We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$20.5M
Cap. Flow
-$12.4M
Cap. Flow %
-6.5%
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125

Top Buys

Rank Stock Value
1
BIPC icon
Brookfield Infrastructure
BIPC
+$1.03M
2
OXLC
Oxford Lane Capital
OXLC
+$1,000K
3
ECC
Eagle Point Credit Company
ECC
+$951K
4
ORAN
Orange
ORAN
+$441K
5
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
+$424K

Top Sells

Rank Stock Value
1
DKL icon
Delek Logistics
DKL
+$2.13M
2
WES icon
Western Midstream Partners
WES
+$888K
3
CNXM
CNX Midstream Partners LP
CNXM
+$744K
4
OSB
Norbord Inc.
OSB
+$695K
5
MPC icon
Marathon Petroleum
MPC
+$594K

Sector Composition

Rank Sector Weight
1 Healthcare 32.34%
2 Real Estate 18.02%
3 Energy 12.43%
4 Materials 10.7%
5 Financials 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
226
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$297K 0.16%
1,748
-238
-12% -$34.3K
EFR
227
Eaton Vance Senior Floating-Rate Fund
EFR
$314M
$296K 0.16%
25,446
-7,352
-22% -$85.7K
MCI
228
Barings Corporate Investors
MCI
$345M
$296K 0.16%
23,711
-2,777
-10% -$36.7K
KRYS icon
229
Krystal Biotech
KRYS
$10.7B
$295K 0.15%
6,846
-938
-12% -$40.7K
SNDX icon
230
Syndax Pharmaceuticals
SNDX
$1.7B
$294K 0.15%
19,894
-2,702
-12% -$41.2K
DCPH
231
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$291K 0.15%
5,678
-781
-12% -$38.3K
MRSN
232
DELISTED
Mersana Therapeutics
MRSN
$288K 0.15%
619
-84
-12% -$42.4K
ALLO icon
233
Allogene Therapeutics
ALLO
$625M
$287K 0.15%
7,611
-1,039
-12% -$39.2K
OCSL icon
234
Oaktree Specialty Lending
OCSL
$1.05B
$286K 0.15%
19,724
-8,045
-29% -$115K
RNAC icon
235
Cartesian Therapeutics
RNAC
$218M
$285K 0.15%
3,834
-523
-12% -$40.1K
XENE icon
236
Xenon Pharmaceuticals
XENE
$6.1B
$284K 0.15%
25,673
-3,497
-12% -$41.1K
BTAI icon
237
BioXcel Therapeutics
BTAI
$24.8M
$281K 0.15%
405
-56
-12% -$42K
YMAB
238
DELISTED
Y-mAbs Therapeutics
YMAB
$281K 0.15%
7,309
-1,000
-12% -$39.8K
TBIO
239
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$280K 0.15%
20,599
-2,796
-12% -$43.1K
FCT
240
First Trust Senior Floating Rate Income Fund II
FCT
$251M
$278K 0.15%
25,376
-4,385
-15% -$48.2K
VVR icon
241
Invesco Senior Income Trust
VVR
$456M
$277K 0.15%
75,800
-24,507
-24% -$87.4K
LITS
242
Lite Strategy Inc
LITS
$32.4M
$276K 0.14%
4,416
-602
-12% -$36.3K
PRVB
243
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$276K 0.14%
21,485
-2,916
-12% -$36.8K
DRNA
244
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$276K 0.14%
15,364
-2,097
-12% -$43.4K
DCF
245
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
$276K 0.14%
34,358
-11,769
-26% -$94.5K
WVE icon
246
Wave Life Sciences
WVE
$1.12B
$272K 0.14%
32,016
-4,345
-12% -$47.6K
VYGR icon
247
Voyager Therapeutics
VYGR
$181M
$271K 0.14%
25,411
-3,463
-12% -$40.6K
BDTX icon
248
Black Diamond Therapeutics
BDTX
$95.1M
$270K 0.14%
8,920
-1,214
-12% -$36.9K
BGT icon
249
BlackRock Floating Rate Income Trust
BGT
$321M
$269K 0.14%
23,969
-5,109
-18% -$57.5K
SGMO
250
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$265K 0.14%
28,049
-3,815
-12% -$41.3K
8 9
10
11 12

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2020 Portfolio in Review

As of Q3 2020, Virtus ETF Advisers held 450 positions worth $191M, down 9.7% from $211M the previous quarter. Its ten largest holdings account for 8% of the portfolio.

Virtus ETF Advisers withdrew a net $12.4M in Q3 2020, closing 125 positions and reducing 215 holdings. Its most notable exit was CNX Midstream Partners LP, an estimated $744K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 34% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Virtus ETF Advisers opened a new position in Oxford Lane Capital worth $1.03M.

  • Virtus ETF Advisers's largest Q3 2020 buy was Oxford Lane Capital: 46,671 shares worth $1.03M.
  • Virtus ETF Advisers added most to Brookfield Infrastructure in Q3 2020, an estimated $1.03M increase.
  • Virtus ETF Advisers's biggest Q3 2020 reduction was Delek Logistics, cutting an estimated $2.13M.
  • Virtus ETF Advisers fully exited CNX Midstream Partners LP in Q3 2020, selling an estimated $744K.
  • Virtus ETF Advisers's ten largest holdings make up 8% of its $191M portfolio in Q3 2020.
  • Virtus ETF Advisers opened 8 new positions and closed 125 in Q3 2020.
  • Virtus ETF Advisers's portfolio value fell 9.7% quarter-over-quarter to $191M.

Based on Virtus ETF Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.